Can I Take Folate with MK-677 (Ibutamoren)?

The Direct Answer: Absence of Evidence Is Not an Interaction Study

The published ibutamoren trials located for this review did not test folate as an interaction, and the authoritative folate sources do not list ibutamoren as a studied co-exposure. No trial compared ibutamoren alone with ibutamoren plus folic acid or L-methylfolate. No validated pharmacokinetic study established that the substances cannot affect each other.

This supports a narrow conclusion: no direct interaction has been documented in the sources reviewed. It does not support the stronger statements that the combination is safe, that absorption pathways never overlap, that no dose separation is needed, or that a particular folate dose protects an ibutamoren user. Those claims appeared in the prior page without supporting experiments.

The larger uncertainty comes from ibutamoren, not ordinary dietary folate. FDA states that ibutamoren is an active ingredient that is not approved and that its safety and efficacy have not been established 1. A person considering the combination should first ask why ibutamoren is being used and whether the unapproved product itself is appropriate.

What MK-677 Is and What Human Trials Actually Show

Ibutamoren, also called MK-677 or MK-0677, is an oral ghrelin-receptor agonist and growth-hormone secretagogue. It increases pulsatile growth-hormone release and raises IGF-1. It is not a selective anabolic agent with proven improvements in strength, recovery, longevity, or athletic performance.

In a randomized trial of 65 adults ages 60 to 81, 25 mg daily increased fat-free mass but did not improve strength or function. Body weight increased, fasting glucose rose by an average of 5 mg/dL, and insulin sensitivity decreased. Increased appetite, transient lower-extremity edema, and muscle pain were among the common adverse effects 2. Those findings cannot be generalized to every age, dose, product, or duration.

Earlier studies confirmed that oral MK-677 can stimulate the GH and IGF-1 axis in older adults 3. Another short trial in adults with obesity found increased GH secretion and fat-free mass, but short duration and surrogate outcomes did not establish long-term clinical benefit 4.

FDA's 2024 review of ibutamoren for pharmacy compounding examined proposed uses including growth-hormone deficiency, osteoporosis, hip fracture, sarcopenia, obesity, and Alzheimer disease. The agency review identified limited effectiveness evidence and safety concerns, including glucose and fluid-related effects 5. A research dose used in a trial is not a recommended consumer dose.

What Folate Does, and When Supplementation Makes Sense

Folate is vitamin B9. It participates in nucleotide synthesis and one-carbon metabolism. Food contains naturally occurring folates, while fortified foods and many supplements contain folic acid. Some supplements use 5-methyltetrahydrofolate, often written as 5-MTHF or L-methylfolate.

Folate needs differ by age, pregnancy and lactation, dietary intake, malabsorption, alcohol exposure, and medication use. People who can become pregnant are advised to obtain folic acid to reduce neural-tube-defect risk. Folate may also be prescribed for documented deficiency or alongside certain medicines, but the correct form and dose depend on the indication.

The NIH Office of Dietary Supplements lists medication interactions involving methotrexate, some antiseizure medicines, and sulfasalazine 6. Ibutamoren is not included as a studied folate interaction. That omission is not proof of compatibility; it reflects the absence of established evidence.

The MTHFR Claim Was Overstated

The MTHFR 677C-to-T variant can reduce enzyme activity and influence homocysteine, especially when folate intake is low. It does not mean a person cannot use folic acid, does not diagnose a “methylation problem,” and does not automatically create a need for L-methylfolate.

NIH notes that research on special supplementation for people with this variant is inconclusive and that CDC still recommends folic acid, rather than 5-MTHF, for people who could become pregnant even when the variant is present 6. Therefore, an MTHFR result is not evidence that folate must be added to an ibutamoren “stack.”

Homocysteine can rise because of vitamin B12 or folate deficiency, kidney disease, hypothyroidism, medications, smoking, age, or genetic factors. Treating the number without identifying the cause can miss vitamin B12 deficiency or renal disease. Routine MTHFR genotyping and a made-up threshold should not substitute for clinical evaluation.

No Evidence Shows That MK-677 Creates a Folate Requirement

The prior page claimed that an ibutamoren-driven increase in IGF-1 raises methyl-donor demand, increases homocysteine, and therefore justifies L-methylfolate. The cited observational study did not test ibutamoren and did not establish that chain of causation. The ibutamoren trials above did not demonstrate folate depletion or a folate-responsive homocysteine problem 2.

There is no validated evidence that MK-677 inhibits MTHFR, blocks folate transport, causes folate deficiency, or creates a special requirement for methylcobalamin. There is also no evidence that folate prevents ibutamoren-associated glucose changes, edema, appetite increase, or other adverse effects.

This matters because a speculative supplement can create false reassurance. Adding folate does not make an unapproved ibutamoren product safer, purer, correctly dosed, or more effective. It also does not replace evaluation of swelling, shortness of breath, glucose changes, numbness, or other symptoms.

Folic Acid, L-Methylfolate, and Dose Limits

For adults, the tolerable upper intake level for folic acid and other synthetic folate forms from supplements and fortified foods is 1,000 mcg daily unless a clinician is supervising a higher dose. The upper limit does not include naturally occurring food folate. For ages 14 to 18, the upper limit is 800 mcg daily 6.

The main concern behind the upper limit is that high folate intake can correct megaloblastic anemia while neurologic injury from vitamin B12 deficiency continues. Folate and vitamin B12 should therefore be interpreted together when deficiency is suspected. The earlier claim that L-methylfolate avoids this masking problem was not supported and has been removed.

L-methylfolate can raise circulating folate, including in people with MTHFR variants. A pharmacokinetic difference does not prove better clinical outcomes for an ibutamoren user. A comparative study found different plasma folate responses to 5-MTHF and folic acid, but it did not involve MK-677, homocysteine-driven sports use, or prevention of ibutamoren adverse effects 7.

Do the Doses Need to Be Separated?

No study established a required separation window, and no study established that taking them together is equivalent to separating them. That leaves no evidence-based timing rule. Folate timing should follow its own indication and product instructions. Ibutamoren should not be self-scheduled from a research protocol as though it were an approved prescription.

The prior recommendation to take MK-677 in the evening to align it with a nocturnal GH pulse was not supported by a clinical comparison of morning versus evening dosing. It has been removed. Likewise, there is no basis for claiming that separation is unnecessary because the products use completely independent transporters and metabolism.

Is There a Standard Lab Panel for the Combination?

No professional guideline provides a baseline-and-eight-week lab protocol for folate plus ibutamoren. The previous page's mandatory homocysteine, red-cell folate, vitamin B12, IGF-1, fasting insulin, and glucose schedule was an invented framework.

Testing should answer a real question. A clinician investigating folate deficiency may use a CBC, vitamin B12, folate testing, diet and medication history, and sometimes methylmalonic acid or homocysteine. A clinician evaluating possible ibutamoren harm may focus on blood pressure, edema, glucose measures, symptoms, other hormone exposures, and the true product contents. The plan changes with diabetes risk, kidney disease, pregnancy, age, and the reason for use.

Normal laboratory results do not prove that a research-market ibutamoren product is safe. Online products can have uncertain identity, dose, purity, and contaminants. A seller's certificate of analysis is not equivalent to FDA approval or pharmacy dispensing under an approved drug application.

Regulatory and Sports Status

Ibutamoren is not an approved drug and is not a lawful dietary-supplement ingredient. In a December 2025 warning letter, FDA explained that ibutamoren was authorized for investigation as a new drug and is excluded from the statutory dietary-supplement definition 8. Calling it a “research compound” does not establish legal retail status, quality, or human safety.

FDA has also warned consumers about a product in which laboratory analysis found undeclared ibutamoren. The agency listed increased appetite, water retention, fatigue, muscle pain, possible changes in glucose metabolism and insulin sensitivity, and possible increased heart-failure risk in certain people 1.

The 2026 World Anti-Doping Agency Prohibited List is in force, and growth-hormone secretagogues including ibutamoren are prohibited for covered athletes 9. A supplement label or physician recommendation does not automatically create an anti-doping exception.

A Safer Decision Framework

If folate was prescribed for pregnancy prevention, deficiency, malabsorption, or a medication-related reason, do not stop it because of an internet interaction page. Confirm the intended form and dose with the prescribing clinician or pharmacist.

If folate is being considered only because someone claimed MK-677 depletes folate, raises homocysteine, or requires “methylation support,” that rationale is not evidence-based. Do not use MTHFR status alone to build a supplement protocol.

If MK-677 is being used, disclose the product and dose to the clinician, including a photo of the label and any lot information. Review swelling, appetite, weight, glucose history, cardiovascular disease, sleep apnea, cancer history, other hormone-active products, and sport rules. Folate does not neutralize those risks.

Prompt medical evaluation is appropriate for shortness of breath, chest pain, rapid or marked swelling, fainting, severe weakness, confusion, symptoms of very high or low glucose, or an allergic reaction. Suspected adverse events can also be reported to FDA MedWatch.